达格列净对伴与不伴痛风心衰患者结局及降尿酸治疗启动的影响
痛风史与主要复合终点风险升高相关(调整HR 1.15,95%CI 1.01-1.31),达格列净在伴与不伴痛风患者中获益一致(交互P=0.66),并减少降尿酸治疗和秋水仙碱的启动。
要点
- 心衰患者中痛风患病率约10.1%,痛风史与更差临床结局独立相关。
- 达格列净在伴与不伴痛风患者中降低主要终点风险的程度一致。
- 达格列净减少新启动降尿酸治疗(HR 0.43)和秋水仙碱(HR 0.54)。
核心结论
- 痛风在心衰患者中常见且与更差结局相关,达格列净的获益在伴与不伴痛风患者中一致,并减少降尿酸治疗和秋水仙碱的启动。
研究设计与样本
- 干预为每日一次10 mg达格列净或安慰剂叠加指南推荐治疗。
- 主要终点为心衰恶化或心血管死亡的复合终点。
主要发现
- 1117例(10.1%)有痛风史,LVEF≤40%组患病率10.3%(488/4747),LVEF>40%组10.1%(629/6258)。
- 痛风患者主要终点发生率为14.7/100人年(95%CI 13.0-16.5),无痛风者为10.5/100人年(95%CI 10.1-11.0),调整HR 1.15(95%CI 1.01-1.31)。
- 达格列净对主要终点的影响在伴痛风者(HR 0.84;95%CI 0.66-1.06)与不伴痛风者(HR 0.79;95%CI 0.71-0.87)中一致,交互P=0.66。
- 达格列净减少降尿酸治疗启动(HR 0.43;95%CI 0.34-0.53)和秋水仙碱启动(HR 0.54;95%CI 0.37-0.80)。
临床怎么用
- 对心衰合并痛风史的患者,达格列净的临床获益与无痛风者一致,可正常使用。
- 达格列净可能减少因高尿酸血症和痛风而新启动降尿酸治疗或秋水仙碱的需求。
局限性
- 为事后汇总分析,痛风史基于基线报告,可能存在分类偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels. OBJECTIVE: To examine the reported prevalence of gout at baseline, the association between gout and clinical outcomes, and the effect of dapagliflozin in patients with and without gout and the introduction of new uric acid-lowering therapy and colchicine. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis used data from 2 phase 3 randomized clinical trials conducted in 26 countries, DAPA-HF (left ventricular ejection fraction [LVEF] ≤40%) and DELIVER (LVEF >40%). Patients with New York Heart Association functional class II through IV and elevated levels of N-terminal pro-B-type natriuretic peptide were eligible. Data were analyzed between September 2022 and December 2022. INTERVENTION: Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of worsening HF or cardiovascular death. RESULTS: Among 11 005 patients for whom gout history was available, 1117 patients (10.1%) had a history of gout. The prevalence of gout was 10.3% (488 of 4747 patients) and 10.1% (629 of 6258 patients) in those with an LVEF up to 40% and greater than 40%, respectively. Patients with gout were more often men (897 of 1117 [80.3%]) than those without (6252 of 9888 [63.2%]). The mean (SD) age was similar between groups, 69.6 (9.8) years for patients with gout and 69.3 (10.6) years for those without. Patients with a history of gout had a higher body mass index, more comorbidity, and lower estimated glomerular filtration rate and were more often treated with a loop diuretic. The primary outcome occurred at a rate of 14.7 per 100 person-years (95% CI, 13.0-16.5) in participants with gout compared with 10.5 per 100 person-years (95% CI, 10.1-11.0) in those without (adjusted hazard ratio [HR], 1.15; 95% CI, 1.01-1.31). A history of gout was also associated with a higher risk of the other outcomes examined. Compared with placebo, dapagliflozin reduced the risk of the primary end point to the same extent in patients with (HR, 0.84; 95% CI, 0.66-1.06) and without a history of gout (HR, 0.79; 95% CI, 0.71-0.87; P = .66 for interaction). The effect of dapagliflozin use with other outcomes was consistent in participants with and without gout. Initiation of uric acid-lowering therapy (HR, 0.43; 95% CI, 0.34-0.53) and colchicine (HR, 0.54; 95% CI, 0.37-0.80) was reduced by dapagliflozin compared with placebo. CONCLUSIONS AND RELEVANCE: This post hoc analysis of 2 trials found that gout was common in HF and associated with worse outcomes. The benefit of dapagliflozin was consistent in patients with and without gout. Dapagliflozin reduced the initiation of new treatments for hyperuricemia and gout. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03036124 and NCT03619213.
引用
- Butt JH, Docherty KF, Claggett BL, et al. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2023. PMID: 36811901. doi:10.1001/jamacardio.2022.5608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。